KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Assets (2017 - 2025)

Historic Return on Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to 0.07%.

  • Biomarin Pharmaceutical's Return on Assets rose 200.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 0.06% for FY2024, which is 400.0% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Return on Assets of 0.07% as of Q3 2025, which was up 200.0% from 0.09% recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Return on Assets high stood at 0.14% for Q2 2021, and its period low was 0.01% during Q4 2021.
  • For the 5-year period, Biomarin Pharmaceutical's Return on Assets averaged around 0.04%, with its median value being 0.02% (2023).
  • Over the last 5 years, Biomarin Pharmaceutical's Return on Assets had its largest YoY gain of 1200bps in 2021, and its largest YoY loss of -1500bps in 2021.
  • Biomarin Pharmaceutical's Return on Assets (Quarter) stood at 0.01% in 2021, then soared by 309bps to 0.02% in 2022, then increased by 10bps to 0.02% in 2023, then skyrocketed by 150bps to 0.06% in 2024, then rose by 12bps to 0.07% in 2025.
  • Its Return on Assets stands at 0.07% for Q3 2025, versus 0.09% for Q2 2025 and 0.07% for Q1 2025.